Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020 The Prostate Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development The prostate cancer pipeline is strong. Currently, approximately 300 molecules are under development in about 400 research and development projects, including preclinical trials. Out of the 400 clinical trials that are currently being conducted for prostate cancer, Phase II clinical trials accounted for 57% while Phase I accounted for 18% followed by Phase III clinical trials. Phase III clinical trials accounted for 12% of the total research and development activities. More than 70% of the total clinical trials involved first-in-class compounds. Approximately 48% of the Phase III clinical trials are being conducted on first-in-class molecules. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--UK-Drug-Forecastsand-Treatment-Analysis-to2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_ Healthcare
Even if a single molecule determines better efficacy and safety profile than the best available treatment regimen in the prostate cancer market, that drug would eventually become a blockbuster and will have the potential to tap the more than $1.1 billion in unmet need that currently exists in the global prostate cancer therapeutics market. This molecule is likely to capture a substantial share of the $57.4m unmet need in the UK prostate cancer therapeutics market. Currently, there are 300 molecules undergoing research and development for various stages of prostate cancer. The clinical trial results of Phase III molecules are highly unpredictable. The failures of clinical trial products such as Sutent (sunitinib), bevacizumab, satraplatin and atrasentan to demonstrate efficacy suggests the unpredictable nature of the clinical trials on leading compounds. In addition, Sanofiaventis is working to gain approval in the European Union (EU). Jevtana is also expected to launch in the UK in the forecast period. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--UK-Drug-Forecastsand-Treatment-Analysis-to2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_ Healthcare
The prostate cancer pipeline also contains vaccines that are being tested for stage III prostate cancer. DCVax is in late-stage clinical development. Based on the successful launch of Provenge, which is a similar vaccine, the market scenario for these vaccines looks positive. Some of the new mechanisms of action that are currently being tested for prostate cancer include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors,
tyrosine kinase inhibitors, DNA synthesis inhibitors, gonadotropin-releasing hormone (GnRH) receptor antagonists and so on. GlobalData's pharmaceutical report, “Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020� is an essential source of information and analysis on the UK prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the UK prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the UK prostate cancer therapeutics market, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--UK-Drug-Forecastsand-Treatment-Analysis-to2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_ Healthcare
Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782